Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research report issued on Friday,Benzinga reports. They currently have a $21.00 target price on the stock. D. Boral Capital’s price objective suggests a potential upside of 389.51% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research report on Thursday, December 12th. HC Wainwright increased their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a report on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Trevi Therapeutics has a consensus rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Trading Down 2.3 %

TRVI opened at $4.29 on Friday. The company has a market cap of $329.76 million, a P/E ratio of -9.75 and a beta of 0.90. The company’s 50 day moving average is $4.14 and its 200-day moving average is $3.50. Trevi Therapeutics has a 1-year low of $2.30 and a 1-year high of $5.05.

Hedge Funds Weigh In On Trevi Therapeutics

A number of hedge funds have recently bought and sold shares of TRVI. JPMorgan Chase & Co. boosted its position in Trevi Therapeutics by 220.6% during the third quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock valued at $336,000 after acquiring an additional 69,167 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Trevi Therapeutics by 10.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after purchasing an additional 117,418 shares during the period. Barclays PLC boosted its position in shares of Trevi Therapeutics by 180.8% during the 3rd quarter. Barclays PLC now owns 95,232 shares of the company’s stock valued at $319,000 after purchasing an additional 61,317 shares in the last quarter. State Street Corp grew its stake in Trevi Therapeutics by 5.9% during the third quarter. State Street Corp now owns 952,912 shares of the company’s stock worth $3,183,000 after purchasing an additional 53,051 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.